ライフサイエンスコーパス: clinical outcome

1 igh frequencies which could influence on the clinical outcome.

2 these patients had a dramatically favorable clinical outcome.

3 ignals that can be used to predict and track clinical outcome.

4 N-MYC, is itself a strong predictor of poor clinical outcome.

5 propriate targeting of therapies to optimize clinical outcome.

6 , as measured on a selected scale, against a clinical outcome.

7 ma, a relatively uncommon cancer with a poor clinical outcome.

8 d after thalamotomy and its correlation with clinical outcome.

9 ority HIV variants on virologic response and clinical outcome.

10 o study disease manifestations and long-term clinical outcome.

11 hus, missing the opportunity for an improved clinical outcome.

12 , globe, lens, ciliary body) correlated with clinical outcome.

13 onary artery disease progression and improve clinical outcome.

14 bal connectivity and TMS/EEG changes tracked clinical outcome.

15 epithelial markers and correlated with poor clinical outcome.

16 specific therapeutic strategies and related clinical outcomes.

17 ed critically ill patients and compared with clinical outcomes.

18 eld using MICC technology, and its effect on clinical outcomes.

19 and there are no reliable methods to predict clinical outcomes.

20 ice may improve our understanding as well as clinical outcomes.

21 h COVID-19 and may be associated with poorer clinical outcomes.

22 limit health care costs without compromising clinical outcomes.

23 uires understanding how biomarkers relate to clinical outcomes.

24 e diagnostic screening for BECTS and predict clinical outcomes.

25 rgical training without negatively impacting clinical outcomes.

26 unclear how the PTEN genotype is related to clinical outcomes.

27 ements in HDL functional characteristics and clinical outcomes.

28 ient selection, payments, length of stay, or clinical outcomes.

29 response to M. tuberculosis and improve TBM clinical outcomes.

30 activated NK cells and predicts unfavorable clinical outcomes.

31 feration levels can predict patient-specific clinical outcomes.

32 iation between achieving an SVR and improved clinical outcomes.

33 in a multicenter setting and on longer-term clinical outcomes.

34 pair, all of which have been associated with clinical outcomes.

35 s the association between occupancy rate and clinical outcomes.

36 o these thresholds is associated with better clinical outcomes.

37 es are potentially associated with important clinical outcomes.

38 that it is difficult to predict their future clinical outcomes.

39 hils to kill Staphylococcus aureus and worse clinical outcomes.

40 sociated with improvements in bronchiectasis clinical outcomes.

41 llular ecosystem of metastatic cancer shapes clinical outcomes.

42 chronic disease of preterm babies with poor clinical outcomes.

43 g pathogenic mechanisms might lead to better clinical outcomes.

44 expression networks correlated with inferior clinical outcomes.

45 but relapse rates are high and lead to poor clinical outcomes.

46 t and blinded assessment of radiological and clinical outcomes.

47 loping transcriptional signatures to predict clinical outcomes.

48 order to design novel strategies to improve clinical outcomes.

49 th distinct electron microscopy profiles and clinical outcomes.

50 as associated with improvement in short-term clinical outcomes.

51 atric surgeries and their relationships with clinical outcomes.

52 ts, and these were associated with favorable clinical outcomes.

53 r research is needed to understand long-term clinical outcomes.

54 D-19 reduced escalation of care and improved clinical outcomes.

55 rkers that may diagnose etiology and predict clinical outcomes.

56 role in disease progression, determining the clinical outcomes.

57 taff exposure with improvement in meaningful clinical outcomes.

58 occlusion of the graft, affecting long-term clinical outcomes.

59 mprove both tooth retention rate and overall clinical outcomes.

60 levels in tumor tissues correlate with poor clinical outcomes.

61 luencing SARS-CoV-2 infectivity and COVID-19 clinical outcomes.

62 ere studied for baseline characteristics and clinical outcomes.

63 nerative outcomes, including preclinical and clinical outcomes.

64 rts to improve the measurement of these core clinical outcomes.

65 e to guideline-recommended care and improves clinical outcomes.

66 ta as a potential mechanism for inconsistent clinical outcomes.

67 MSTs were compared with each other and with clinical outcomes.

68 istry staining and correlated with patients' clinical outcomes.

69 ctively; P < .01), as well as more favorable clinical outcomes (96% vs 72%, respectively; P < .01), w

70 ccurrence of vascular complications (VC) and clinical outcomes according to secondary access (transfe

71 correlated with rural residence, we compared clinical outcomes across four groups (Rural/Individual,

72 bsessive-compulsive behaviour and to predict clinical outcomes across the cohort.

73 mechanism, as suggested from murine data and clinical outcome after topical antipsoriatic treatment i

74 ve the proportion of patients achieving good clinical outcomes after endovascular thrombectomy compar

75 However, data describing clinical outcomes after MCS in this population are limit

76 III colorectal cancer (CRC) exhibit various clinical outcomes after radical treatments.

77 s provide an explanation for the paradoxical clinical-outcomes after ADT, possibly due to SPINK1 upre

78 oncern as patients with RCC have the poorest clinical outcomes among all CRC patients.

79 correlates with increased morbidity and poor clinical outcomes among patients living with human immun

80 n medicine can be applied to rapidly improve clinical outcome and reduce the risk of toxicity.

81 d macrophages (TAM) is associated with worse clinical outcome and resistance to therapy.

82 o the timing of the AST result contribute to clinical outcome and that further intervention may be re

83 ycystic kidney disease (ARPKD) and long-term clinical outcome and to identify risk factors for severe

84 ared to less frequent screening will improve clinical outcomes and be cost-effective.

85 aradoxical relationship was observed between clinical outcomes and costs among racial and ethnic mino

86 ach which may reveal cellular mechanisms for clinical outcomes and could be applied to other conditio

87 cus on disease management (to reduce adverse clinical outcomes and disease progression among patients

88 various epigenetic age estimators for human clinical outcomes and health/life span.

89 Observed differences in clinical outcomes and hemodynamic performance may guide

90 abologenomic events which may correlate with clinical outcomes and identified nuclear genes involved

91 d emergency personnel, would help to improve clinical outcomes and reduce unnecessary costs in patien

92 on on the impact of manufacturing changes on clinical outcomes and report on unique CD22 CAR T-cell t

93 parameter predicting protection against all clinical outcomes and stages of HCMV infection.

94 The aims of this study were to evaluate the clinical outcomes and survival of furcation-involved tee

95 Clinical outcomes and valve performance were assessed up

96 variant can contribute to this diversity of clinical outcomes and what is the mechanistic basis for

97 roportionately low costs compared with their clinical outcomes and whether adding social determinants

98 scribe trends and variations in Impella use, clinical outcomes, and costs across US hospitals in pati

99 ations between patient and hospital factors, clinical outcomes, and total Medicare spending for the 9

100 d the infection rate, clinical presentation, clinical outcomes, and transmission dynamics for severe

101 ortunately, large neuroimaging datasets with clinical outcome annotations are typically limited, espe

102 ase and moderate or severe ischemia, whether clinical outcomes are better in those who receive an inv

103 clear, and effective therapies for improving clinical outcomes are lacking.

104 Data on clinical outcomes are scarce but include several reports

105 Cardiac morphology and clinical outcomes are similar in patients with truncatin

106 Our findings demonstrate that the HPV+ OPSCC clinical outcomes are strongly correlated with the TIME,

107 Volumetric magnetic resonance imaging and clinical outcome assessments (pain, quality of life, dis

108 Including clinical outcome assessments, such as patient- reported

109 d predictors of immunity, susceptibility and clinical outcome associated with infection.

110 Excellent 5-year visual and clinical outcomes associated with a 2-piece MK in cases

111 balloon pumps (IABPs), little is known about clinical outcomes associated with intravascular microaxi

112 disease, PCI was associated with an inferior clinical outcome at 5 years compared with CABG.

113 therapy has the potential to predict patient clinical outcomes based on primary, but not metastatic,

114 sarcomeric proteins, the ability to predict clinical outcomes based on specific mutations in HCM pat

115 surance with regards to equivalent long-term clinical outcomes based upon donor sex.

116 ween LVMi regression at 1-year post-TAVR and clinical outcomes between 1 and 5 years.

117 erally poor, yet considerable differences in clinical outcomes between individual patients exist.

118 We sought to compare clinical outcomes between participants whose weaning tri

119 There were no significant differences in clinical outcomes between the transfusion strategies.

120 the ERL is not inferior to MIST in terms of clinical outcomes but is superior in PROs for the surgic

121 e a deleterious impact on multiple sclerosis clinical outcomes but it is unclear whether this is medi

122 ciated with cancer subtype, grades, and poor clinical outcomes, but also facilitated primary tumor gr

123 will be important not only to improve their clinical outcomes, but also their quality of life.

124 tion volumes can serve as a guide to predict clinical outcomes, but that this is not the sole determi

125 ults suggest that TDP modulation may improve clinical outcomes by reducing pain intensity and possibl

126 r, among patients within the same stage, the clinical outcome can be very different.

127 r investigation is warranted to determine if clinical outcomes can be improved using this methodology

128 ivation, which might translate into improved clinical outcomes compared with dyssynchronous ventricul

129 tiviral therapy was associated with improved clinical outcomes compared with no SVR.

130 P+BL combination therapy results in improved clinical outcomes compared with treatment with DAP alone

131 Microbiology, management, and clinical outcomes data from patients with filtering-asso

132 m October 2014 through July 2017, safety and clinical outcomes data were collected under a registry f

133 Patient demographics, procedure details, and clinical outcomes data were extracted.

134 modulations (TEMs) to understand speech, and clinical outcomes depend on the accuracy with which thes

135 mposes a major threat to achieving optimized clinical outcomes during cancer treatment.

136 ciation of these differentiation states with clinical outcomes during immune checkpoint blockade and

137 ine recommended therapies for CAD as well as clinical outcomes (emergency department presentation for

138 both continuous and discrete variables (e.g. clinical outcomes, environmental factors) as well as int

139 hat this dysbiosis can predispose to adverse clinical outcomes, especially including acute intestinal

140 ine survey, a literature review on available clinical outcomes, expert opinion, and alignment with wo

141 were associated with a safer, more favorable clinical outcome for patients with COVID-19 pneumonia.TR

142 Here, we report the clinical outcomes for a prospective cohort of incarcerat

143 s improving a number of short- and long-term clinical outcomes for patients requiring ICU care.

144 have shown tremendous promise for improving clinical outcomes for patients with advanced cutaneous m

145 AR T recipients, we report overall favorable clinical outcomes for patients with COVID-19 without act

146 gs that inhibit TNFalpha has led to improved clinical outcomes for patients with rheumatoid arthritis

147 gressive CSCs that may substantially improve clinical outcomes for patients with TNBC, who currently

148 In addition, clinical outcomes for the treatment of rCDI (n = 31), as

149 r VCA type, immunosuppression treatment, and clinical outcomes for VCAs.

150 ignificant differences were observed between clinical outcome groups in the left and right spinothala

151 predictive signatures of phenotypes such as clinical outcome has not been attained in almost any dis

152 s not well defined, and its correlation with clinical outcome has not been fully studied.

153 APL cell processes, and its association with clinical outcome, has not, however, been established.

154 rosis (AF) was significantly associated with clinical outcomes (hazard ratio [95% confidence interval

155 r major findings were as follows: (1) severe clinical outcome (ICU treatment) was associated with hig

156 Linking epigenetic marks to clinical outcomes improves insight into molecular proces

157 Both complications were associated with poor clinical outcome in a similar percentage of participants

158 /6 inhibitors and endocrine therapy improves clinical outcome in advanced oestrogen receptor (ER)-pos

159 -2 RNA in serum at admission correlated with clinical outcome in COVID-19.

160 s (GRP78, ATF6 and PERK) and correlated with clinical outcome in EOC.

161 ges in both NOX2 and TRPM8 mRNA predict poor clinical outcome in estrogen receptor (ER)-negative brea

162 DM7B) was significantly associated with poor clinical outcome in HER2-negative GC.

163 ession of CD4 and has the potential to alter clinical outcome in human prostate cancer, where low lev

164 There was no evidence that S44819 improved clinical outcome in patients after ischaemic stroke, and

165 based risk score for predicting survival and clinical outcome in patients with Acute Myeloid Leukaemi

166 we conclude that PAX2 contributes to better clinical outcome in tamoxifen treated ER-positive breast

167 umor concentrations were not associated with clinical outcome in this exploratory study.

168 riod from June 2017 to May 2019, we assessed clinical outcomes in 79 patients diagnosed with TCMR 1A/

169 tive assessment of test performance based on clinical outcomes in ACLF patients.

170 autoregulation asymmetry, and poor long-term clinical outcomes in acutely comatose patients.

171 determine whether biopsy-proven NASH impacts clinical outcomes in CHB patients and assess prognostic

172 We compared survival and clinical outcomes in elderly recipients with low immunol

173 yocardial fibrosis is a major determinant of clinical outcomes in heart failure (HF) patients.

174 t of telomere maintenance mechanism (TMM) on clinical outcomes in high-risk neuroblastoma, we integra

175 res revealed by scRNA-seq were biomarkers of clinical outcomes in independent cohorts.

176 ic stem cell transplantation (HSCT) improves clinical outcomes in KD patients only if delivered pre-s

177 olic dysfunction, and associated with poorer clinical outcomes in medically-managed AS.

178 We aim to determine the long-term clinical outcomes in MS, and to identify early prognosti

179 Clinical outcomes in multiple sclerosis (MS) are highly

180 ationship between TIME, tobacco exposure and clinical outcomes in OPSCC patients (n = 143) with exten

181 s are associated with significantly improved clinical outcomes in patients with advanced HF and impla

182 bolic phenotypes and may limit these adverse clinical outcomes in patients with HCM.

183 ogical and metabolic remodeling, and adverse clinical outcomes in patients with HCM.

184 d diastolic cardiac dysfunction and impaired clinical outcomes in patients with nonischemic heart dis

185 d psychosis (DUP) is associated with adverse clinical outcomes in patients with psychosis spectrum di

186 entions and the poor translation into better clinical outcomes in patients.

187 a need to develop noninvasive predictors of clinical outcomes in persons with HIV/HCV coinfection.

188 itive effects of food and food components on clinical outcomes in RA, but insufficient evidence exist

189 acrophage activation syndrome (MAS) and poor clinical outcomes in severe inflammatory and septic cond

190 Furthermore, surgery has shown to improve clinical outcomes in such cases, indicating the viabilit

191 tatus changes were associated with long-term clinical outcomes in the COAPT population.

192 carry independent prognostic information for clinical outcomes in the UK Biobank, a population-based

193 of COVID-19 among HCWs and their associated clinical outcomes in the United States.

194 identify patients at risk for poor long-term clinical outcomes in this population.

195 t AUD treatment patterns and their impact on clinical outcomes in this population.

196 patterns, healthcare resource use (HCRU) and clinical outcomes in this setting.

197 mor microenvironment (TME) is linked to poor clinical outcomes in treatment of resistant breast cance

198 reserve and a key contributor to suboptimal clinical outcomes in various lung disease groups.

199 he proportion of Impella use, and associated clinical outcomes (in-hospital mortality, bleeding requi

200 ditions are associated with numerous adverse clinical outcomes including falls, fractures, and increa

201 h milder phenotype for most of the evaluated clinical outcomes, including age at loss of ambulation (

202 and examine their ability to predict adverse clinical outcomes [increased length of stay (LOS) and co

203 V had a higher-risk profile and more adverse clinical outcomes, irrespective of the vessel treated.

204 In human Ebola virus infection, clinical outcome is strongly associated with the initial

205 Nevertheless, the lack of clinical outcomes is sometimes used as the reason for he

206 ERPs improve short and long-term mortality, clinical outcomes, length of stay, and discharge disposi

207 pt future studies to examine GCs' effects on clinical outcomes likely dependent on functional adaptiv

208 More objective means for predicting PAS and clinical outcome may be provided by MRI descriptors.

209 nning, patient education, and as a means for clinical outcome measurement.

210 s umbilical cord blood and, as part of their clinical outcome measures, were imaged with diffusion MR

211 egardless of ADA status correlated with poor clinical outcome (median sample PASI 10.1, 6.5 [95% CI =

212 will correlate with ventilator settings and clinical outcomes.Methods: Magnetic resonance images of

213 ombolysis-In-Cerebral-Infarction 2b-3), good clinical outcome (modified Rankin Scale 0-2), complicati

214 Finally, we found evidence that short-term clinical outcome (National Institute of Health Stroke Sc

215 icant relationships between baseline SMD and clinical outcomes, nor between ORR, irAEs and baseline S

216 Better clinical outcomes occur with opportune weaning compared

217 Severe clinical outcomes occurred commonly in PWH and COVID-19.

218 relative to Ecc BSI, was predictive of poor clinical outcome (odds ratio 3.3; 95% confidence interva

219 t in ALN(-) at diagnosis could influence the clinical outcome of BC patients.

220 ne response to coronaviruses, as well as the clinical outcome of coronavirus-mediated disease.

221 ficiency hinder objective assessments of the clinical outcome of cultivated limbal epithelial cell tr

222 senchymal subtype are associated with a poor clinical outcome of HGSC.

223 etween the effect of gene carriage and CC on clinical outcome of IMI.

224 he secondary outcome was a composite adverse clinical outcome of intubation, intensive care unit admi

225 , we report that tumor DCs are linked to the clinical outcome of patients with breast cancer who rece

226 the time of diagnosis, are relevant for the clinical outcome of patients with this disease.

227 gy of the graph and to predict the phenotype/clinical outcome of patients.

228 Based on the clinical outcome of these events, individualized treatme

229 taneous allergen immunotherapy predicted the clinical outcome of this treatment.

230 Fluid resuscitation improves clinical outcomes of burn patients; however, its executi

231 ic target that could potentially improve the clinical outcomes of cancer patients.

232 virus 2 infection has a direct impact on the clinical outcomes of coronavirus disease 2019 patients.

233 logy, pathophysiology, emerging therapy, and clinical outcomes of coronavirus disease 2019; and based

234 nd lungs has consequences on infectivity and clinical outcomes of COVID-19.

235 lness is unknown.Objectives: To determine if clinical outcomes of critically ill patients are predict

236 reporting innovative strategies that improve clinical outcomes of critically ill patients boarded in

237 e-gene expression signature, which predicted clinical outcomes of ER-positive breast cancer patients,

238 are not strong predictors of the detrimental clinical outcomes of interest.

239 Herein, we report clinical outcomes of intestinal transplantation without

240 I-DRB regulatory gene may be associated with clinical outcomes of malaria in Plasmodium-infected indi

241 To assess the safety and clinical outcomes of multi-probe stereotactic radiofrequ

242 h included hydroxychloroquine, would improve clinical outcomes of patients admitted to the hospital w

243 treatment (including revascularization), and clinical outcomes of patients with a first-time MI.

244 Here, we report the epidemiology and clinical outcomes of patients with CNS infections from a

245 ther prevention of CMV reactivation improves clinical outcomes of patients with critical illness and

246 Despite the generally favorable clinical outcomes of patients with HPV driven (HPV+) OPS

247 Baseline characteristics and clinical outcomes of patients with or without CA up to 3

248 e of microbial exposures on inflammatory and clinical outcomes of patients with severe asthma (SA).

249 All chest radiographs and clinical outcomes of patients, including those who were

250 e potential changes in Medicare payments and clinical outcomes of referring high-risk surgical patien

251 he application of GM in RET led to favorable clinical outcomes of root development without inflammato

252 Despite the good clinical outcomes of total joint replacements, prostheti

253 um tuberculosis affects immune responses and clinical outcomes of tuberculosis (TB).

254 scribed clinical characteristics and adverse clinical outcomes of U.S. invasive Hia cases detected th

255 f anti-inflammatory drugs which have limited clinical outcomes only when dosed within the early time

256 CM and ongoing assessment aimed at improving clinical outcomes, particularly surrounding liver transp

257 RP+S resulted in significant improvements in clinical outcomes (PD and CAL, BOP) from baseline to 12

258 twork functioning both predicted and tracked clinical outcome, potentially opening the door to treatm

259 psychosis onset and enhance the accuracy of clinical outcome prediction in CHR-P individuals, with t

260 re consistent for coagulation biomarkers and clinical outcomes, providing reassuring data on efficacy

261 The risk of adverse clinical outcomes remains substantial even when initiati

262 evidence on the effects of HCV screening on clinical outcomes remains unavailable, but DAA regimens

263 WH with normal lipid levels requires further clinical outcome research.

264 The primary efficacy endpoint was clinical outcome (responder rate) on day 14.RESULTSClini

265 with COVID-19 and correlated these data with clinical outcomes.RESULTSPatients with COVID-19 showed d

266 The resulting patient Clinical Outcomes Scores (COS) were used to optimize the

267 ngitudinal atlases and integrating them with clinical outcomes should help identify novel predictive

268 acokinetics, pharmacodynamics, toxicity, and clinical outcomes suggest these agents have limited clin

269 ted with more serious side effects and worse clinical outcomes than FK506.

270 with EVT appear to be associated with better clinical outcomes than SBP of <180mmHg.

271 op diuretics had significantly better 30-day clinical outcomes than those not discharged on loop diur

272 ach provides an early diagnosis and a better clinical outcome that can only be given from the recogni

273 vascularized herpetic corneal scars achieves clinical outcomes that remain stable for up to 10 years

274 r (BC) therapy is associated with aggressive clinical outcomes; thus, herein we present structural op

275 to reveal cell subsets linked to continuous clinical outcomes to generate new therapeutic and biomar

276 tervention and its use is supported by large clinical outcome trials.

277 o identify humans at highest risk of adverse clinical outcomes upon infection, who may most benefit f

278 Clinical outcomes vary among youths at clinical high ris

279 markers were validated by linking them with clinical outcomes (visual acuity, lesion activity and re

280 and was associated with favorable long-term clinical outcomes, warranting the performance of an adeq

281 Primary clinical outcomes were all-cause mortality and heart fai

282 Clinical outcomes were analysed post hoc by baseline fra

283 Clinical outcomes were analyzed according to the seconda

284 Clinical outcomes were as good in the LG AS groups with

285 Categorical clinical outcomes were ascertained by chart review, and

286 OVID-19 diagnosis, and course of illness and clinical outcomes were collected.

287 Epidemiology and clinical outcomes were compared between patients with al

288 tegies were reviewed, and predictors of poor clinical outcomes were determined through multivariable

289 Environmental exposures, health history, and clinical outcomes were prospectively recorded for 111 fa

290 All data relative to the clinical outcomes were recorded.

291 Clinical outcomes were similar at 5 years, except chest

292 idence interval]) associated with developing clinical outcomes were: prior hepatic decompensations (3

293 The RAPCO trials (Radial Artery Patency and Clinical Outcomes) were designed to compare the long-ter

294 e feasibility of conducting an RCT with hard clinical outcomes when such trials are unavailable.

295 Global connectivity changes predicted clinical outcome, while both global connectivity and TMS

296 Data on long-term clinical outcomes with a novel ultrathin drug-eluting st

297 mature and delayed weaning groups had poorer clinical outcomes with fewer ventilator-free days (-2.18

298 This review article focuses on current clinical outcomes with novel perfusion strategies in org

299 Common variants in GRK5 may modify clinical outcomes with PAR4 inhibitors, and upregulation

300 duce in-person visits with comparable 30-day clinical outcomes within an integrated care delivery fra